---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-026195"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:35:49.729355+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences Q2 net loss widens to $19.2M; advances nsPFA clinical programs with FDA IDE submissions

## Summary
- GAAP net loss ($19.2M) vs ($11.4M) YoY; non-GAAP net loss ($13.7M) vs ($9.0M).
- Cash $106.3M at June 30 (down from $119.3M at March 31); operating cash burn $12.8M in Q2.
- FDA IDE applications submitted for nsPFA cardiac surgical clamp and 360° catheter AF pivotal studies.
- Over 140 benign thyroid nodule patients treated; expanded pilot program; post-market study enrollment planned Q3 2025.

## SEC filing metadata
- accession: 0001437749-25-026195
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774925026195/0001437749-25-026195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774925026195/plse20250604_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-026195
- JSON: https://secwatch.observer/filing/0001437749-25-026195.json
- Plain text: https://secwatch.observer/filing/0001437749-25-026195.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.